#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Autoimmune myositis Juvenile psoriatic arthritis Exudative retinopathy Cytomegalovirus infection Angiosarcoma Nodal marginal zone B-cell lymphoma Anaplastic large cell lymphoma T- and null-cell types Rhabdomyosarcoma recurrent Cholestatic pruritus Congenital cystic kidney disease Squamous cell carcinoma of the cervix Neoplasm malignant Hypereosinophilic syndrome Myelodysplastic syndrome Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndrome More trials…

    Learn about Rare Diseases

    Marginal zone lymphoma Glomerulonephritis membranoproliferative – Diagnostics Progressive multifocal leukoencephalopathy – Life with Disease Chondrosarcoma Carcinoid syndrome – Trials in Disease Angiosarcoma recurrent – Trials in Disease Ewing’s sarcoma – Treatment Sjogren’s syndrome VEXAS syndrome – Diagnostics Hereditary angioedema with C1 esterase inhibitor deficiency – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ifosfamide GOVORESTAT Pembrolizumab Imiglucerase Laronidase ASP2957 Bdc-1001 Gskvx000000014593 Etranacogene Dezaparvovec Nido-361 Metamizole Magnesium Ropivacaine GS-4321 Ulonivirine Ursodeoxycholic Acid Apitegromab SALICYLIC ACID IDP-121 Ublituximab Pemigatinib More therapies…

    Learn about Your Condition

    Marginal zone lymphoma Hepatic encephalopathy Anal cancer stage II Cerebral palsy Diabetic gastroparesis Factor IX deficiency Shock Mite allergy SAPHO syndrome Colorectal adenoma Tetanus Aortic disorder Anogenital warts Klinefelter's syndrome Methylmalonic acidaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Multiple sclerosis

  • Study on the Effects of Annual vs. Semi-Annual Ocrelizumab Infusions in Patients with Active Multiple Sclerosis After 2 Years of Initial Treatment

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    France

  • Comparison of ocrelizumab and rituximab treatment in adults with active relapsing-remitting multiple sclerosis

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Ocrelizumab
    • Rituximab
    Norway Sweden

  • Indapamide for Reducing Disability Progression in Adults with Primary and Secondary Progressive Multiple Sclerosis

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • INDAPAMIDE HEMIHYDRATE
    The Netherlands

  • Safety and Tolerability of Oral SUN-627 in Adults with Non‑Active Progressive Multiple Sclerosis (SPMS/PPMS) – Phase 2a Study

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Finland

  • Randomized Study of Tolebrutinib Versus Rituximab in Adults with Multiple Sclerosis

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Multiple sclerosis
    • Relapsing multiple sclerosis
    Investigated Drugs:
    • Tolebrutinib
    • Rituximab
    Sweden

  • Study of the safety and effectiveness of tolDC therapy in patients with progressive forms of multiple sclerosis

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Multiple sclerosis
    Investigated Drugs:
    • Toldc
    Belgium Spain
Previous Page
1 2 3 4 5 … 10
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!